SINTX Technologies Faces Cash Crunch Despite FDA Foot Device Win
SINTX Technologies details 2025 operations and risks
2026.03.20Updated 25d ago
SINTX Technologies’ 2025 annual report highlights $10.4M net loss, $4.1M cash, new SiNAPTIC foot and ankle FDA clearance, and an extensive silicon nitride patent portfolio and risk factors.
AI SummaryPowered by AI
SINTX Technologies reported a $10.4M net loss in 2025 with only $4.1M in cash reserves. The medical device company secured FDA clearance for its new SiNAPTIC foot and ankle implant. The firm's extensive silicon nitride patent portfolio provides competitive advantage amid significant operational risks.
Original Article
Read full article on sourcesintx technologiessinaptic implantfda clearancesilicon nitridemedical devicesorthopedicpatent portfoliocash reservessintxtechnologies
Explore More
Related News
pH7 Technologies: C$55 Million Series B Closed To Scale Critical Minerals Extraction Technology
Pulse 2.0 · 2026.04.15
Top 12 Front End Technologies for 2026
2026.04.15
Inspira Technologies Initiates AME Technology Implementation with Major U.S. Customer
2026.04.14
Moschip Technologies Ltd is Rated Sell
2026.04.14
Dell Technologies Soars On Takeover Rumor - Will NVIDIA Make The Move? - Dell Technologies (NYSE:DELL)
Benzinga · 2026.04.14
CoinHix Revolutionizing Coin Collecting with AI Technology
Respect My Region · 2026.04.15